PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences
May 26 2016 - 9:20AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that Kenneth L.
Waggoner, the Chief Executive Officer of PharmaCyte, will be a
featured presenter at the 5th Annual Marcum MicroCap Conference on
Thursday, June 2, 2016, in New York City at the Grand Hyatt Hotel.
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, lesser-known public companies with less than
$500 million in market capitalization. The Marcum MicroCap
Conference is dedicated to providing a forum where these companies
can network with the investment community. The event attracts fund
managers and high net worth investors who focus on small cap
equities, a number of whom Mr. Waggoner will be meeting.
In addition to the Marcum MicroCap Conference, PharmaCyte will
be well represented at the 52nd Annual Meeting of the American
Society of Clinical Oncology (ASCO), which will be held from June
3-7 in Chicago at McCormick Place. During ASCO, PharmaCyte will
host a medical and scientific discussion of its therapy for
pancreatic cancer among top oncologist investigators who have
expressed interest in PharmaCyte’s technology and possible
participation in the clinical trial. Joining Mr. Waggoner will be
Dr. Gerald W. Crabtree, PharmaCyte’s Chief Operating Officer, and
Dr. Sanjay Batra, PharmaCyte’s Senior Business Development
Advisor.
Presentations will be made by Prof. Dr. Walter Gunzburg and Dr.
Brian Salmons, co-developers of the Cell-in-a-Box®, technology, Dr.
Matthias Löhr, the Principal Investigator in the two previous
clinical trials using the Cell-in-a-Box® technology, and Dr. Manuel
Hidalgo, one of the principal architects of PharmaCyte’s trial
design. Prof. Gunzburg and Dr. Salmons will explain the development
of the technology, the mechanism of action and the encapsulation
process. Dr. Löhr will present data from the two previous trials
and discuss placement of the capsules in the patients involved. Dr.
Hidalgo will discuss the trial design and rationale for it, and
solicit feedback from the oncologists in attendance.
PharmaCyte will also be attending the 2016 BIO International
Convention (BIO) being held June 6-9, at the Moscone Center in San
Francisco. PharmaCyte’s Chief Executive Officer will be meeting
with companies involved in the clinical trial, companies interested
in PharmaCyte’s product candidates and others critical to the
success of the development of those products. BIO’s annual
convention attracts over 15,000 biotechnology and pharmaceutical
leaders who come together for one week of intensive networking to
discover new opportunities and promising partnerships. This event
covers a wide spectrum of life science applications.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified live cells that convert
an inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body
(ifosfamide) is then given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been placed. When the ifosfamide, which
is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the chemotherapy drug takes
place at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com